YUTIQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUTIQ (YUTIQ).
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
| Metabolism | Fluocinolone acetonide is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Intravitreal fluocinolone acetonide is released slowly and undergoes local metabolism; systemic absorption is minimal. |
| Excretion | Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%. |
| Half-life | Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Following systemic absorption, Vd is approximately 99 L (1.4 L/kg for a 70 kg adult), indicating extensive tissue distribution. |
| Bioavailability | Intravitreal administration results in local ocular availability; systemic bioavailability is negligible (<1% of administered dose). |
| Onset of Action | Therapeutic effect on inflammation typically observed within 2 weeks following intravitreal implantation. |
| Duration of Action | Up to 36 months (3 years) due to continuous release of fluocinolone acetonide from the implant. |
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
| Dosage form | IMPLANT |
| Renal impairment | No dose adjustment required; pharmacokinetics unaffected by renal impairment. |
| Liver impairment | No dose adjustment required; not studied in hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; use caution due to higher susceptibility to corticosteroid effects (e.g., intraocular pressure elevation, cataract progression). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YUTIQ (YUTIQ).
| Breastfeeding | Fluocinolone acetonide is excreted in human milk following systemic administration. The milk-to-plasma ratio is unknown. Because of potential for serious adverse reactions in nursing infants, including adrenal suppression and growth retardation, women should discontinue breastfeeding prior to treatment. Alternatively, avoid use during lactation. |
| Teratogenic Risk | YUTIQ (fluocinolone acetonide intravitreal implant) is contraindicated in pregnancy due to proven teratogenicity in animal studies. In rats and rabbits, systemic corticosteroids including fluocinolone acetonide produced fetal resorptions, cleft palate, and delayed ossification at doses below the human exposure level. There are no adequate human studies. The implant releases corticosteroid over 36 months, resulting in sustained systemic exposure. First trimester exposure carries highest risk for structural anomalies; second and third trimester use may impair fetal growth and adrenal function. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to fluocinolone acetonide or any component; active ocular infections (bacterial, fungal, viral, including herpes simplex); advanced glaucoma with uncontrolled IOP; aphakia with damage to posterior capsule.
| Precautions | Increased intraocular pressure (IOP) requiring monitoring and possible glaucoma surgery; cataract formation; endophthalmitis (sterile and infectious); retinal detachment; vitreous hemorrhage; corneal edema; exacerbation of ocular infections; corticosteroid-induced systemic effects (rare with intravitreal use). |
Loading safety data…
| Fetal Monitoring | If YUTIQ is inadvertently used in pregnancy, monitor fetal growth with serial ultrasound assessments due to risk of intrauterine growth restriction (IUGR). Assess amniotic fluid volume. After delivery, evaluate the neonate for signs of adrenal insufficiency (e.g., hypoglycemia, hypotension, poor feeding). Maternal monitoring includes blood pressure, blood glucose, and signs of infection due to corticosteroid immunosuppression. |
| Fertility Effects | In animal studies, high doses of systemic corticosteroids impaired fertility in rats, characterized by prolonged estrous cycles and reduced implantation. In humans, chronic corticosteroid use can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially altering menstrual cycles and ovulation. Reversible infertility may occur. YUTIQ's sustained corticosteroid release could similarly affect fertility. Advise patients of possible temporary impairment. |